Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16431194 | 1.00 | PPARA (0.47) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL16431193 | 1.00 | PPARA (0.47) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL5188191 | 0.98 | PPARA (0.48) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL11482457 | 0.98 | PPARA (0.48) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL6598890 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL3128974 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL8345723 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL3129770 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL21518030 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E | |
| SCHEMBL13725844 | 0.86 | PPARA (0.62) | PPARACNR1CNR2FAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3937917-B1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | UNIV OREGON STATE (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | PPARA 4228/4885CNR1 57/4885CNR2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.